logo
  

Staples Q3 Results Top View - Quick Facts

Office supplies retailer Staples Inc. (SPLS) Wednesday said third-quarter profit increased from the prior year, despite a slide in revenues.

Net income for the quarter increased to $216.79 million from last year's $135.23 million. Earnings per share grew to $0.34 from $0.21.

Earnings per share from continuing operations was flat with last year at $0.34. Adjusted earnings per share from continuing operations totaled $0.37, while it was $0.42 last year.

On average, 17 analysts polled by Thomson Reuters expected earnings of $0.36 per share for the quarter. Analysts' estimates typically exclude special items.

Sales slipped to $5.962 billion from $6.112 billion in the prior year. Analysts expected revenues of $5.93 billion.

Ron Sargent, Staples' chairman and chief executive officer, said, "We're building momentum as we reinvent Staples. During the third quarter, we accelerated growth in our delivery businesses, gained traction in categories beyond office supplies, and changed the way we work to drive cost savings."

For the fourth quarter, the company expects sales to decrease from the prior year. The firm expects to achieve adjusted earnings per share in the range of $0.27 to $0.32 for the quarter, while analysts look for $0.31per share.

For the full year, the company expects to generate more than $800 million of free cash flow, an increase from the previous guidance of more than $600 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT